Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BNBioNTech SE logo

BioNTech SE (BNTX)

NASDAQ Global Select · Currency in USD
$88.12 ▼ -1.56 (-1.73%)
At close: Oct 23, 4:00 PM ET. Market closed.
$88.40 ▲ +0.29 (+0.32%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$89.67
Open
$89.34
Day's Range
$87.52 – $89.86
52 Week Range
$79.52 – $124.00
Volume
838,377
Avg. Volume
1,126,407
Market Cap
$22.13B
Beta (5Y Monthly)
1.25
PE Ratio (TTM)
--
EPS (TTM)
-$6.70
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Jun 2, 2022
1y Target Est
$120.33

Profile: BioNTech SE

Sector
Healthcare
Industry
Biotechnology
Full-time employees
7,807
CEO
Ugur Sahin

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate $0.88 · Revenue est. $1.17B
DateEst.Actual
Aug 4, 2026-$2.40-$3.70Miss
May 5, 2026-$2.54-$2.43Beat
Mar 10, 2026-$0.22-$1.44Miss
Nov 3, 2025-$1.12-$0.14Beat
Aug 4, 2025-$2.69-$1.82Beat
May 5, 2025-$2.48-$1.82Beat

Analyst view

Consensus price target
$120.33 ▲ +36.6%
Range $96.00 – $140.00
Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on BNTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.